Drugs & Targets FDA grants Fast Track designation for lunresertib + zedoresertib for genomic-defined platinum-resistant ovarian cancer April 24, 2026Vol.52 No.16
Drugs & Targets EU approves Ojemda as first targeted therapy in r/r pediatric low-grade glioma regardless of BRAF alteration April 24, 2026Vol.52 No.16
Drugs & Targets FDA issues draft guidance on genome editing safety standards April 17, 2026Vol.52 No.15
Drugs & Targets FDA clears first HPV self-collection kit and assay for at-home use, marking a step toward improving screening uptake April 10, 2026Vol.52 No.14
Drugs & Targets Nuvalent submits NDA to FDA for neladalkib in TKI pre-treated advanced ALK-positive NSCLC April 10, 2026Vol.52 No.14
Drugs & Targets FDA approves Ponlimsi to increase bone mass, including for breast and prostate cancer patients April 03, 2026Vol.52 No.13
Drugs & Targets FDA grants priority review to Elevar Therapeutics’s lirafugratinib as second-line cholangiocarcinoma treatment April 03, 2026Vol.52 No.13
Drugs & Targets FDA and EC approve Opdivo IO combinations in classical Hodgkin Lymphoma March 27, 2026Vol.52 No.12
Drugs & Targets FDA approves relacorilant + nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer March 27, 2026Vol.52 No.12
